Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211873 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
A Phase 3 study, sponsored by Guerbet.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
NCT01211873 is a Phase 3 study that has completed, run by Guerbet. The registered enrollment target is 416 participants.
The verdict
NCT01211873, a Phase 3 study, has completed, sponsored by Guerbet.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.
Interventions
- DRUG Dotarem (gadoterate meglumine)
- DRUG Magnevist (gadopentetate dimeglumine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211873
The ClinicalTrials.gov registry entry for NCT01211873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guerbet, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dotarem (gadoterate meglumine) is the first listed.
NCT01211873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01211873 about?
NCT01211873 is a clinical study titled "Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions". The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.
What is the current status of trial NCT01211873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2010-09. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01211873?
The interventions under investigation include: Dotarem (gadoterate meglumine) (DRUG), Magnevist (gadopentetate dimeglumine) (DRUG).
Who is sponsoring clinical trial NCT01211873?
This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.